BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 27424476)

  • 1. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
    Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
    Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
    Oberg HH; Peipp M; Kellner C; Sebens S; Krause S; Petrick D; Adam-Klages S; Röcken C; Becker T; Vogel I; Weisner D; Freitag-Wolf S; Gramatzki M; Kabelitz D; Wesch D
    Cancer Res; 2014 Mar; 74(5):1349-60. PubMed ID: 24448235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
    Helm O; Mennrich R; Petrick D; Goebel L; Freitag-Wolf S; Röder C; Kalthoff H; Röcken C; Sipos B; Kabelitz D; Schäfer H; Oberg HH; Wesch D; Sebens S
    PLoS One; 2014; 9(5):e94357. PubMed ID: 24797069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression.
    Grage-Griebenow E; Jerg E; Gorys A; Wicklein D; Wesch D; Freitag-Wolf S; Goebel L; Vogel I; Becker T; Ebsen M; Röcken C; Altevogt P; Schumacher U; Schäfer H; Sebens S
    Mol Oncol; 2014 Jul; 8(5):982-97. PubMed ID: 24746181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity.
    Gonnermann D; Oberg HH; Lettau M; Peipp M; Bauerschlag D; Sebens S; Kabelitz D; Wesch D
    Front Immunol; 2020; 11():1328. PubMed ID: 32695112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells.
    Oberg HH; Wesch D; Kalyan S; Kabelitz D
    Front Immunol; 2019; 10():1690. PubMed ID: 31379875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase of Tumor Infiltrating γδ T-cells in Pancreatic Ductal Adenocarcinoma Through Remodeling of the Extracellular Matrix by a Hyaluronan Synthesis Suppressor, 4-Methylumbelliferone.
    Suto A; Kudo D; Yoshida E; Nagase H; Suto S; Mimura J; Itoh K; Hakamada K
    Pancreas; 2019 Feb; 48(2):292-298. PubMed ID: 30589828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on γδ T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells.
    Jonescheit H; Oberg HH; Gonnermann D; Hermes M; Sulaj V; Peters C; Kabelitz D; Wesch D
    Cells; 2020 May; 9(5):. PubMed ID: 32384638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
    Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
    Raj D; Yang MH; Rodgers D; Hampton EN; Begum J; Mustafa A; Lorizio D; Garces I; Propper D; Kench JG; Kocher HM; Young TS; Aicher A; Heeschen C
    Gut; 2019 Jun; 68(6):1052-1064. PubMed ID: 30121627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival.
    Xu YF; Lu Y; Cheng H; Shi S; Xu J; Long J; Liu L; Liu C; Yu X
    Pancreatology; 2014; 14(4):295-301. PubMed ID: 25062880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.
    Liu C; Cheng H; Luo G; Lu Y; Jin K; Guo M; Ni Q; Yu X
    Int J Oncol; 2017 Aug; 51(2):686-694. PubMed ID: 28714519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3
    Wang X; Lang M; Zhao T; Feng X; Zheng C; Huang C; Hao J; Dong J; Luo L; Li X; Lan C; Yu W; Yu M; Yang S; Ren H
    Oncogene; 2017 May; 36(21):3048-3058. PubMed ID: 27991933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.